Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 6/20 | 0.68 |
| ▸ | DRD2 | P14416 | 5/20 | 0.68 |
| ▸ | DRD3 | P35462 | 5/20 | 0.68 |
| ▸ | HTR7 | P34969 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | HTR6 | P50406 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8550773 | 0.85 | DRD4 (0.55) | DRD4DRD2DRD3MAPTNPSR1 | |
| SCHEMBL6864941 | 0.83 | DRD4 (0.81) | DRD4DRD2DRD3HTR7KDM4E | |
| SCHEMBL844542 | 0.83 | DRD2 (0.51) | DRD4DRD2DRD3TDP1KDM4E | |
| SCHEMBL17996843 | 0.81 | ALDH1A1 (0.50) | DRD4DRD2DRD3TDP1KDM4E | |
| SCHEMBL5854967 | 0.80 | SLC6A2 (0.56) | MAPTTDP1L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL418557 | 0.80 | DRD4 (0.57) | DRD4DRD2DRD3HTR7MAPT | |
| SCHEMBL18699541 | 0.79 | DRD2 (0.48) | DRD4DRD2DRD3MAPTNPSR1 | |
| SCHEMBL10713747 | 0.79 | ALDH1A1 (0.55) | DRD2DRD3MAPTTDP1L3MBTL1 | |
| SCHEMBL18699453 | 0.78 | DRD4 (0.47) | DRD4DRD2DRD3MAPTNPSR1 | |
| SCHEMBL22092310 | 0.78 | DRD2 (0.63) | DRD4DRD2DRD3MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11312708-B2 | Process and intermediates for the preparation of benzo[b]thiophene compounds | CRYSTAL PHARMA, S.A.U. (ES) | 2022-04-26 | — | — | US | disclosed |
| US-20200172523-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF BENZO[B]THIOPHENE COMPOUNDS | CURIA SPAIN, S.A.U. (ES) | 2020-06-04 | — | — | US | disclosed |
| US-20190040048-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF BENZO[B]THIOPHENE COMPOUNDS | CURIA SPAIN, S.A.U. (ES) | 2019-02-07 | — | — | US | disclosed |
| EP-3150591-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF BENZO[B]THIOPHENE COMPOUNDS | Crystal Pharma S.A.U (ES) | 2017-04-05 | — | — | EP | disclosed |
| WO-1997044334-A2 | NOVEL PIPERAZINE OR HOMOPIPERAZINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND A PROCESS FOR THEIR PREPARATION | EGIS Gyógyszergyár Rt. (HU) | 1997-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172523-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF BENZO[B]THIOPHENE COMPOUNDS | CYP4X1, CYP2B6, CYP2C19 | DRD4 413/4885DRD2 1035/4885DRD3 1031/4885 |
| US-20190040048-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF BENZO[B]THIOPHENE COMPOUNDS | CYP4X1, CYP2B6, CYP2C19 | DRD4 413/4885DRD2 1035/4885DRD3 1031/4885 |
| US-11312708-B2 | Process and intermediates for the preparation of benzo[b]thiophene compounds | CYP4X1, CYP2B6, CYP2C19 | DRD4 413/4885DRD2 1035/4885DRD3 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.